Singapore HSA Reaches WHO Top Tier For Medical Device Regulation

Singapore’s Health Sciences Authority is now the first regulator anywhere to hold the World Health Organization’s top rating for medical device oversight. The WHO confirmed on 10 March 2026 that the HSA had reached Maturity Level 4, the highest classification in its benchmarking system for national authorities, after assessing how the agency handles devices from first approval through to post-market policing. Health Minister Ong Ye Kung broke the news in his opening speech at the 29th session of the International Medical Device Regulators Forum, which Singapore was hosting and chairing that same week. The venue was chosen for effect. The substance underneath it is real.

The first regulator to clear WHO’s top bar for devices

The rating comes out of the WHO Global Benchmarking Tool Plus for medical devices, or GBT+MD, an extension of the framework the organization already uses to grade national systems for medicines and vaccines. A team of international experts, working with WHO staff from headquarters and the Regional Office for the Western Pacific, assessed the HSA in February 2026 against more than 260 indicators. Those cover the whole span of a device’s life: product registration and market authorization, laboratory testing, clinical trials oversight, post-market surveillance, and the inspection and licensing of manufacturers and distributors. Maturity Level 4 means the system runs at an advanced level of performance and keeps improving itself, rather than just clearing a minimum bar.

Dr Yukiko Nakatani, WHO Assistant Director-General for Health Systems, Access and Data, framed the stakes plainly: “Effective regulation is essential to ensure that health products, including medical devices, reaching patients are safe, effective and of assured quality.” The WHO attached a number that deserves more attention than the award itself: only 32% of regulatory authorities worldwide have the capacity to fully ensure that medicines, vaccines and other health products meet required standards of safety, quality and effectiveness.

That 32% figure is the real story. Two thirds of the world’s regulators cannot fully verify the products used in their own hospitals, so they borrow decisions from agencies that can. Every regulator that reaches the top of the WHO ladder becomes a lending library for the rest. Singapore just became the first one for devices, and that is worth considerably more than the plaque.

What the rating covers, and what it does not

One point is worth being precise about, because it trips up patients and procurement teams alike: ML4 is a verdict on the regulator, not a seal on any individual product. No device becomes “WHO approved” because of this. What the rating tells you is that the process behind Singapore’s approvals has been audited, end to end, at the highest grade the WHO applies.

The process itself is worth knowing if you deal with the Singapore market. Devices there are regulated under the Health Products Act of 2007 and the Health Products (Medical Devices) Regulations of 2010, and sorted into four risk classes, from Class A for the lowest-risk products up to Class D for the highest. Devices in Classes B through D must be registered with the HSA before they can be supplied. Class A devices are exempt from product registration, a deliberate piece of proportionality, but the exemption is narrower than it sounds. Dealers still need a licence to manufacture, import or wholesale them, are assessed against Good Distribution Practice requirements, and stay on the hook for change notifications, adverse event reporting and field safety corrective actions if a health risk emerges after sale.

For a patient flying in for treatment, the practical translation is modest but real. The scanners, implants and diagnostics used on you in a Singapore hospital pass through a system the WHO has now audited at its top grade. That does not rank the surgeon or the hospital. It does mean the narrower question, whether anyone competent vetted the device itself, has a better answer in Singapore than almost anywhere else.

A credential stack a decade in the making

The device rating slots into a longer sequence. The HSA reached ML4 for medicines and imported vaccines in 2022. The WHO designated it a Listed Authority for medicines in 2023, expanded that listing in 2024 to cover all regulatory functions for the medicines product stream, and has recognized it as a Stringent Regulatory Authority for high-risk in vitro diagnostics since 2023. In 2026 the agency chairs the Management Committee of the IMDRF, the club of major device regulators whose Singapore session ran from 9 to 13 March and drew over 400 regulators and industry delegates. HSA chief executive Adjunct Professor Raymond Chua kept his public reaction short: “It is a great honor for Singapore’s Health Sciences Authority to be recognized at the highest WHO Maturity Level (ML4) classification for medical device regulation.”

The stack matters because of how regulation actually spreads. Reaching ML4 is the qualifying round for WHO Listed Authority status, the designation that lets other countries formally anchor their own approvals to yours. The HSA already holds it for medicines. If a device-stream listing follows, an HSA approval stops being a purely national decision and becomes something closer to an export product. Manufacturers can do this arithmetic too. With around 200 device makers in the country producing everything from in vitro diagnostics to software as a medical device, filing in Singapore first starts to look like the efficient route into every market that leans on HSA paperwork.

The regulator picks up a sales brief

What interests me most is what the HSA announced alongside the award. The same 10 March press release unveiled an expanded economic development role: a new industry development function run with the Economic Development Board, Enterprise Singapore, the research agency A*STAR and the Agency for Care Effectiveness. The numbers attached are not small. Singapore’s research and innovation plan, RIE2030, allocates S$37 billion, about US$29 billion, over the next five years. About 100 industry-sponsored clinical trials start in the country every year. Biopharmaceutical manufacturing output doubled over two decades to S$13.9 billion in 2023, while medtech output grew about tenfold over the same period, from S$1.8 billion in 2003 to S$18.9 billion in 2023. The HSA also launched AIHGle 2.0, revised AI-in-healthcare guidelines co-developed with the health ministry, and put out an AI-enabled tool for industry feedback that gives developers automated preliminary risk classification estimates while a product is still in development.

A regulator formally taking on industry promotion is the kind of arrangement that normally earns a raised eyebrow, and it should here too. The referee has started selling tickets. Singapore’s wager is that the ML4 audit is precisely the counterweight that makes the dual role safe, and the sequencing supports it: the agency invited the WHO to grade its rigor in February, then announced the sales brief in March, in that order. The AI classification tool is the piece I would actually watch. A credible early read on whether your product lands in Class B or Class C is worth months to a small developer, and that sort of unglamorous plumbing decides where startups choose to file first.

What This Means

Strip away the ceremony and three things changed on 10 March. Patients who travel to Singapore for treatment now sit inside the only device regulation system the WHO has audited at its top grade, which will not pick their hospital for them but does close off one category of doubt. Manufacturers gained a reason to treat Singapore as a first-filing market, because HSA sign-off is on its way to becoming currency that other regulators accept. And every other WHO member state gained a working answer key, since the GBT+MD assessment Singapore passed is published methodology, not magic. Two open questions remain. Does a WHO device-stream listing follow the ML4 rating, and does the new industry development desk stay visibly separate from the people doing the evaluations? I would expect the first within a couple of years. The second is the one to hold them to.